MedTrace Logo

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

NCT02846324 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2020-10-20

Study results available
· View outcomes & findings →

Summary

This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.

Conditions

Interventions

DRUG

GBT440

Capsules which contain GBT440 drug substance in Swedish orange

DRUG

Placebo

Placebo capsules

Sponsors & Collaborators

  • Global Blood Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-09-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846324 on ClinicalTrials.gov